NewLink and Roche Pair Off on Cancer Immunotherapy
Insights - NewLink (NLNK) and Roche (RHHBY) will collaborate on the development of new IDO inhibitors, and combinations with NLNK's NLG919.
Read nowAuthor Archives: Editorial Staff
If You Visited Us this Week You Knew Exactly Where to Look for the Rally
Insights - In last week’s biotech recap, and again at PropThink.com this week, we outlined some key support levels for the S&P 500 (SPX or SPY), explaining … Continue Reading
Read now
Why 1800 (or thereabouts) for the S&P 500 is So Interesting
Insights - Multiple reasons for support, 1800 on the SPX/SPY is an interesting level to watch. No, it's not time to panic.
Read now
Shire and AbbVie May Be Going Their Own Ways as Lawmakers Crack Down
Insights - AbbVie (ABBV) is walking back its plan to buy Shire Plc (SHPG) on concerns over new U.S. laws making it harder for American companies to lower taxes through inversions, or … Continue Reading
Read now
First Pharma Giant to Report, J&J Posts Strong Third Quarter
Insights - Johnson & Johnson (JNJ) reported third quarter earnings on Tuesday and $18.5 billion in revenue (+5.1% over the quarter a year ago), with net earnings of $4.7 billion … Continue Reading
Read nowWeekly Recap: Don’t Worry, You’re Not Alone
Actavis to Buy Durata: Fellow Antibiotic Developers Get Some Love
Insights - Actavis (ACT) continued its acquisition spree on Mondau morning with the purchase of Durata Therapeutics (DRTX) in a deal valued at $675 million. The Dublin based … Continue Reading
Read now